EDP Biotech Corporation Debuts CA1-18 Tumor Marker Assay For Early Stage Colorectal Cancer

Published: Oct 16, 2006

KNOXVILLE, TN -- (MARKET WIRE) -- October 13, 2006 -- EDP Biotech Corporation (EDP), a diagnostics company focused on the development and sale of immunodiagnostic tests for humans, today announced the development of the CA1-18 Enzyme Immunoassay (EIA) to be used as an aid in the diagnosis and management of the colorectal cancer patient.

Back to news